IL6 and melanoma: We used a highly sensitive WST‐1 cell proliferation assay to assess the antiproliferative effect of BRAFi treatment following direct inhibition of IL‐6 and WNT5A signalling in HTB63‐R and A375‐R BRAFi‐R melanoma cell lines.